Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2013, Article ID 517239, 6 pages
http://dx.doi.org/10.1155/2013/517239
Research Article

Serum Anti-Müllerian Hormone Levels in Patients with Epithelial Ovarian Cancer

1Department of Obstetrics and Gynecology, L. Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Ulica Ujejskiego 75, 85-168 Bydgoszcz, Poland
2Department of Laboratory Medicine, L. Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Ulica Jurasza 5, 85-094 Bydgoszcz, Poland

Received 10 May 2013; Revised 28 June 2013; Accepted 5 July 2013

Academic Editor: Kai J. Buhling

Copyright © 2013 Pawel Walentowicz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objectives. The aim of our study was to examine serum anti-Müllerian hormone (AMH) concentration in ovarian cancer patients in relation to clinicopathological features, such as a pathological subtype of the tumor, (FIGO) stage, grading, and overall 5-year survival. Material and Methods. We enrolled 72 epithelial ovarian cancer patients in our study, aged 45–79 years, who underwent optimal cytoreductive surgery. In all patients, serum AMH concentration was measured using a two-step sandwich type enzyme immunoassay before surgery. As a reference value for women over 45 years we accepted anti-Müllerian hormone concentration below 1 ng/mL. Results. In the whole group of patients with ovarian cancer, median serum concentration of AMH was 0.07 (0.0–0.37) ng/mL, whereas in the group of those with positive AMH values (≥0.14 ng/mL) it was 0.31 (0.15–0.73) ng/mL. No significant correlation was found between serum AMH levels and FIGO stage, histological subtype, or grading ( ). The analysis of five-year survival rate related to AMH levels showed no statistically significant differences. There were no differences in survival rates between patients with positive or negative serum AMH levels. Conclusion. Measurement of serum anti-Müllerian hormone levels was not useful in predicting clinicopathological features and survival in patients with ovarian cancer.